Related Experiment Videos
In vitro antiproliferative and metabolic activity of eight novel 5-fluorinated uracil nucleosides
B J Braakhuis1, G W Visser, I Stringer
1Department of Otolaryngology/Head and Neck Surgery, Free University Hospital, Amsterdam, the Netherlands.
Abstract:
The in vitro growth inhibitory activity of eight novel 5-fluorinated uracil nucleosides was assessed in four human tumour cell lines, one of colon and three of head and neck squamous cell origin. These compounds are ribose or deoxyribose sugars with an acetoxy or an hydroxyl-group at the 6-position in the uracil part of the molecule, and their respective diastereoisomers. Antiproliferative effects were tested in an automated microculture assay based on the reduction of a tetrazolium dye, the MTT assay. Using a continuous drug exposure for four days, all novel nucleosides were more potent inhibitors of cell growth than 5-fluorouracil (5-FU). Most drugs were very active, having an IC50 value at least 10 fold lower than that of 5-FU, and this was consistently found for all cell lines. The 6-acetoxy compounds were generally more active than the compounds with a hydroxyl-group at the 6-position, while diastereoisomerism did not seem to influence the antiproliferative effect. Their capacity to inhibit the incorporation of tritiated deoxyuridine into DNA, which reflects the inhibition of thymidylate synthase, was measured in a short term assay. When tested at a concentration of 10(-6) mol/l, most of the compounds were found to block this incorporation more efficiently than 5-FU.
Insights
Eight novel 5-fluorinated uracil nucleosides demonstrated superior in vitro growth inhibition against cancer cells compared to 5-fluorouracil (5-FU). These compounds effectively suppressed tumor cell proliferation and DNA synthesis, offering potential as new anticancer agents.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Pharmacology
Background:
- 5-fluorouracil (5-FU) is a widely used chemotherapeutic agent.
- Development of novel nucleoside analogs is crucial for overcoming drug resistance and improving efficacy.
- Targeting thymidylate synthase remains a key strategy in cancer chemotherapy.
Purpose of the Study:
- To synthesize and evaluate the in vitro anticancer activity of novel 5-fluorinated uracil nucleosides.
- To compare the antiproliferative effects of these novel compounds with 5-FU.
- To investigate the mechanism of action, specifically thymidylate synthase inhibition.
Main Methods:
- Synthesis of eight novel 5-fluorinated uracil nucleosides with variations in sugar moiety and uracil substitution.
- In vitro antiproliferative activity assessed using the MTT assay in human colon and head and neck squamous cell carcinoma lines.
- Inhibition of DNA synthesis measured by tritiated deoxyuridine incorporation assay.
Main Results:
- All novel nucleosides exhibited significantly greater growth inhibitory activity than 5-FU across all tested cell lines (IC50 at least 10-fold lower).
- 6-acetoxy substituted compounds were generally more potent than their 6-hydroxyl counterparts.
- Most compounds effectively inhibited thymidylate synthase activity at 10(-6) mol/l, surpassing 5-FU's efficacy.
Conclusions:
- Novel 5-fluorinated uracil nucleosides show promising in vitro anticancer potential.
- These compounds represent a significant advancement over 5-FU in terms of potency and mechanism of action.
- Further investigation into these nucleoside analogs is warranted for their development as cancer therapeutics.